NEW YORK (GenomeWeb) – Admera Health today announced it has completed a Series A financing round.

The New Jersey-based molecular diagnostics firm did not disclose the sum raised in the funding round, but said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.

The financing round was led by investment firm Prime Value Capital Management (PVCM) and was joined by Sungent Bioventure, a venture capital firm based in Suzhou, China. PVCM's founding partner Chenhui Wen will join Admera's board of directors, Admera said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.